|
|
Human Clinical Study Summary
|
Authors
|
Purpose
|
Finding
|
Pub. Status
|
|
Lembcke et al.
|
Safety and
Nutrition
|
Safe in children with malnutrition;
Increased protein and energy retention
|
Published
|
|
Hanning et al.
|
Safety and
Nutrition
|
Safe in young adults;
Increased plasma amino acids
|
Unpub.
|
|
Begin et al.
|
Growth and
Morbidity
|
Safe for use in breast-fed infants;
Tendency for reduced days with persistent diarrhea
|
Published
|
|
Earnest et al.
|
Blood lipids
|
ImmunoLin lowered total and LDL cholesterol
|
Published
|
|
Weaver et al.
|
Morbidity
|
Reduced days with diarrheal symptoms
|
Unpub.
|
|
Bishop et al.
|
Safety and
Morbidity
|
ImmunoLin is safe for use in ped. IBD patients
|
Unpub.
|
|
Marcos et al.
|
Body Weight
|
Decreased involuntary weight loss
|
Unpub.
|
|